Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Frank B Cortazar; John L Niles; David R W Jayne; Peter A Merkel; Annette Bruchfeld; Huibin Yue; Thomas J Schall; Pirow Bekker; ADVOCATE Study Group

doi:10.1016/j.ekir.2023.01.039

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Standard

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. / Cortazar, Frank B; Niles, John L; Jayne, David R W; Merkel, Peter A; Bruchfeld, Annette; Yue, Huibin; Schall, Thomas J; Bekker, Pirow; ADVOCATE Study Group.

In: KIDNEY INT REP, Vol. 8, No. 4, 04.2023, p. 860-870.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Cortazar, FB, Niles, JL, Jayne, DRW, Merkel, PA, Bruchfeld, A, Yue, H, Schall, TJ, Bekker, P & ADVOCATE Study Group 2023, 'Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan', KIDNEY INT REP, vol. 8, no. 4, pp. 860-870. https://doi.org/10.1016/j.ekir.2023.01.039

APA

Cortazar, F. B., Niles, J. L., Jayne, D. R. W., Merkel, P. A., Bruchfeld, A., Yue, H., Schall, T. J., Bekker, P., & ADVOCATE Study Group (2023). Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. KIDNEY INT REP, 8(4), 860-870. https://doi.org/10.1016/j.ekir.2023.01.039

Vancouver

Cortazar FB, Niles JL, Jayne DRW, Merkel PA, Bruchfeld A, Yue H et al. Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan. KIDNEY INT REP. 2023 Apr;8(4):860-870. https://doi.org/10.1016/j.ekir.2023.01.039

Bibtex

@article{930b0ccc42b647e0809d01139a6103fd,

title = "Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan",

abstract = "INTRODUCTION: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m2 in the avacopan group and 4.1 ml/min per 1.73 m2 in the prednisone group (P = 0.029) at week 52. This new analysis examines the results in the patient subgroup with severe renal insufficiency at enrollment into the trial, i.e., eGFR ≤20 ml/min per 1.73 m2.METHODS: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups.RESULTS: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR ≤20 ml/min per 1.73 m2. At week 52, eGFR increased on average 16.1 and 7.7 ml/min per 1.73 m2 in the avacopan and prednisone groups, respectively (P = 0.003). The last eGFR value measured during the 52-week treatment period was ≥2-fold higher than baseline in 41% of patients in the avacopan group compared to 13% in the prednisone group (P = 0.030). More patients in the avacopan group versus prednisone group had increases in eGFR above 20, 30, and 45 ml/min per 1.73 m2, respectively. Serious adverse events occurred in 13 of 27 patients (48%) in the avacopan group and 16 of 23 patients (70%) in the prednisone group.CONCLUSION: Among patients with baseline eGFR ≤20 ml/min per 1.73 m2 in the ADVOCATE trial, eGFR improved more in the avacopan group than in the prednisone group.",

author = "Cortazar, {Frank B} and Niles, {John L} and Jayne, {David R W} and Merkel, {Peter A} and Annette Bruchfeld and Huibin Yue and Schall, {Thomas J} and Pirow Bekker and {ADVOCATE Study Group} and I Kotter",

note = "{\textcopyright} 2023 International Society of Nephrology. Published by Elsevier Inc.",

year = "2023",

month = apr,

doi = "10.1016/j.ekir.2023.01.039",

language = "English",

volume = "8",

pages = "860--870",

journal = "KIDNEY INT REP",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "4",

}

RIS

TY - JOUR

T1 - Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

AU - Cortazar, Frank B

AU - Niles, John L

AU - Jayne, David R W

AU - Merkel, Peter A

AU - Bruchfeld, Annette

AU - Yue, Huibin

AU - Schall, Thomas J

AU - Bekker, Pirow

AU - ADVOCATE Study Group

AU - Kotter, I

PY - 2023/4

Y1 - 2023/4

N2 - INTRODUCTION: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m2 in the avacopan group and 4.1 ml/min per 1.73 m2 in the prednisone group (P = 0.029) at week 52. This new analysis examines the results in the patient subgroup with severe renal insufficiency at enrollment into the trial, i.e., eGFR ≤20 ml/min per 1.73 m2.METHODS: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups.RESULTS: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR ≤20 ml/min per 1.73 m2. At week 52, eGFR increased on average 16.1 and 7.7 ml/min per 1.73 m2 in the avacopan and prednisone groups, respectively (P = 0.003). The last eGFR value measured during the 52-week treatment period was ≥2-fold higher than baseline in 41% of patients in the avacopan group compared to 13% in the prednisone group (P = 0.030). More patients in the avacopan group versus prednisone group had increases in eGFR above 20, 30, and 45 ml/min per 1.73 m2, respectively. Serious adverse events occurred in 13 of 27 patients (48%) in the avacopan group and 16 of 23 patients (70%) in the prednisone group.CONCLUSION: Among patients with baseline eGFR ≤20 ml/min per 1.73 m2 in the ADVOCATE trial, eGFR improved more in the avacopan group than in the prednisone group.

AB - INTRODUCTION: In the 330-patient ADVOCATE trial of avacopan for the treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, in which 81% of patients had renal involvement, estimated glomerular filtration rate (eGFR) increased on average 7.3 ml/min per 1.73 m2 in the avacopan group and 4.1 ml/min per 1.73 m2 in the prednisone group (P = 0.029) at week 52. This new analysis examines the results in the patient subgroup with severe renal insufficiency at enrollment into the trial, i.e., eGFR ≤20 ml/min per 1.73 m2.METHODS: eGFR was determined at baseline and over the course of the trial. Changes in eGFR were compared between the 2 treatment groups.RESULTS: In ADVOCATE, 27 of 166 patients (16%) in the avacopan group and 23 of 164 patients (14%) in the prednisone group had a baseline eGFR ≤20 ml/min per 1.73 m2. At week 52, eGFR increased on average 16.1 and 7.7 ml/min per 1.73 m2 in the avacopan and prednisone groups, respectively (P = 0.003). The last eGFR value measured during the 52-week treatment period was ≥2-fold higher than baseline in 41% of patients in the avacopan group compared to 13% in the prednisone group (P = 0.030). More patients in the avacopan group versus prednisone group had increases in eGFR above 20, 30, and 45 ml/min per 1.73 m2, respectively. Serious adverse events occurred in 13 of 27 patients (48%) in the avacopan group and 16 of 23 patients (70%) in the prednisone group.CONCLUSION: Among patients with baseline eGFR ≤20 ml/min per 1.73 m2 in the ADVOCATE trial, eGFR improved more in the avacopan group than in the prednisone group.

U2 - 10.1016/j.ekir.2023.01.039

DO - 10.1016/j.ekir.2023.01.039

M3 - SCORING: Journal article

C2 - 37069984

VL - 8

SP - 860

EP - 870

JO - KIDNEY INT REP

JF - KIDNEY INT REP

SN - 2468-0249

IS - 4

ER -